Page last updated: 2024-12-11

mycothiazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

mycothiazole: from Cacospongia mycofijiensis; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6443333
CHEMBL ID4540502
CHEBI ID69137
MeSH IDM0496026

Synonyms (10)

Synonym
mycothiazole
carbamic acid, ((4z,7r)-8-(4-((2z)-2,5-hexadienyl)-2-thiazolyl)-7-hydroxy-8-methyl-3-methylene-4-nonenyl)-, methyl ester
(-)-mycothiazole
114582-75-1
(r)-(-)-mycothiazole
methyl n-[(z,7r)-8-[4-[(2e)-hexa-2,5-dienyl]-1,3-thiazol-2-yl]-7-hydroxy-8-methyl-3-methylidenenon-4-enyl]carbamate
CHEBI:69137
Q27137476
CHEMBL4540502
DTXSID301037231
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
thiazolesAn azole in which the five-membered heterocyclic aromatic skeleton contains a N atom and one S atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (15)

Assay IDTitleYearJournalArticle
AID1578535Drug degradation assessed as methyl N-[(E)-8-[4-[(2E)-hexa-2,5-dienyl]-1,3-thiazol-2-yl]-3,7-dihydroxy-3-(hydroxymethyl)-8-methylnon-4-enyl]carbamate metabolite formation by measuring relative abundance measured after preserving compound in amber vial con2020ACS medicinal chemistry letters, Feb-13, Volume: 11, Issue:2
Reinvestigation of Mycothiazole Reveals the Penta-2,4-dien-1-ol Residue Imparts Picomolar Potency and 8
AID1578528Drug degradation assessed as methyl N-[(E)-8-[4-[(2E)-hexa-2,5-dienyl]-1,3-thiazol-2-yl]-3,7-dihydroxy-3-(hydroxymethyl)-8-methylnon-4-enyl]carbamate metabolite formation by measuring maximum absorbance units measured after preserving compound in amber vi2020ACS medicinal chemistry letters, Feb-13, Volume: 11, Issue:2
Reinvestigation of Mycothiazole Reveals the Penta-2,4-dien-1-ol Residue Imparts Picomolar Potency and 8
AID1578530Drug degradation assessed as methyl N-[(E)-8-[4-[(2E)-hexa-2,5-dienyl]-1,3-thiazol-2-yl]-3,7-dihydroxy-3-(hydroxymethyl)-8-methylnon-4-enyl]carbamate metabolite formation by measuring maximum absorbance units measured after preserving compound in amber vi2020ACS medicinal chemistry letters, Feb-13, Volume: 11, Issue:2
Reinvestigation of Mycothiazole Reveals the Penta-2,4-dien-1-ol Residue Imparts Picomolar Potency and 8
AID1578529Drug degradation assessed as methyl N-[(E)-8-[4-[(2E)-hexa-2,5-dienyl]-1,3-thiazol-2-yl]-3,7-dihydroxy-3-(hydroxymethyl)-8-methylnon-4-enyl]carbamate metabolite formation by measuring maximum absorbance units measured after preserving compound in amber vi2020ACS medicinal chemistry letters, Feb-13, Volume: 11, Issue:2
Reinvestigation of Mycothiazole Reveals the Penta-2,4-dien-1-ol Residue Imparts Picomolar Potency and 8
AID1578537Drug degradation assessed as methyl N-[(E)-8-[4-[(2E)-hexa-2,5-dienyl]-1,3-thiazol-2-yl]-3,7-dihydroxy-3-(hydroxymethyl)-8-methylnon-4-enyl]carbamate metabolite formation by measuring relative abundance measured after preserving compound in amber vial con2020ACS medicinal chemistry letters, Feb-13, Volume: 11, Issue:2
Reinvestigation of Mycothiazole Reveals the Penta-2,4-dien-1-ol Residue Imparts Picomolar Potency and 8
AID1578539Stability of compound assessed as shelf life measured after preserving compound in amber vial containing 95% CH3CN and 5% H2O followed by drying using N2 stream and later punged-with argon in dark desiccator under vacuum for 24 hrs2020ACS medicinal chemistry letters, Feb-13, Volume: 11, Issue:2
Reinvestigation of Mycothiazole Reveals the Penta-2,4-dien-1-ol Residue Imparts Picomolar Potency and 8
AID1578536Drug degradation assessed as methyl N-[(E)-8-[4-[(2E)-hexa-2,5-dienyl]-1,3-thiazol-2-yl]-3,7-dihydroxy-3-(hydroxymethyl)-8-methylnon-4-enyl]carbamate metabolite formation by measuring relative abundance measured after preserving compound in amber vial con2020ACS medicinal chemistry letters, Feb-13, Volume: 11, Issue:2
Reinvestigation of Mycothiazole Reveals the Penta-2,4-dien-1-ol Residue Imparts Picomolar Potency and 8
AID1578534Drug degradation assessed as methyl N-[(E)-8-[4-[(2E)-hexa-2,5-dienyl]-1,3-thiazol-2-yl]-3,7-dihydroxy-3-(hydroxymethyl)-8-methylnon-4-enyl]carbamate metabolite formation by measuring relative abundance measured after preserving compound in amber vial con2020ACS medicinal chemistry letters, Feb-13, Volume: 11, Issue:2
Reinvestigation of Mycothiazole Reveals the Penta-2,4-dien-1-ol Residue Imparts Picomolar Potency and 8
AID1578525Cytotoxicity against human PANC1 cells assessed as reduction in cell viability incubated for 3 days by tryphan blue dye based assay2020ACS medicinal chemistry letters, Feb-13, Volume: 11, Issue:2
Reinvestigation of Mycothiazole Reveals the Penta-2,4-dien-1-ol Residue Imparts Picomolar Potency and 8
AID1578533Drug degradation assessed as methyl N-[(E)-8-[4-[(2E)-hexa-2,5-dienyl]-1,3-thiazol-2-yl]-3,7-dihydroxy-3-(hydroxymethyl)-8-methylnon-4-enyl]carbamate metabolite formation by relative abundance measured after preserving compound in amber vial containing 952020ACS medicinal chemistry letters, Feb-13, Volume: 11, Issue:2
Reinvestigation of Mycothiazole Reveals the Penta-2,4-dien-1-ol Residue Imparts Picomolar Potency and 8
AID1578540Stability of compound assessed as shelf life measured after preserving compound in amber vial containing 95% CH3CN and 5% H2O followed by drying using N2 stream and later punged-with argon followed by exposure to 4 degC for 24 hrs2020ACS medicinal chemistry letters, Feb-13, Volume: 11, Issue:2
Reinvestigation of Mycothiazole Reveals the Penta-2,4-dien-1-ol Residue Imparts Picomolar Potency and 8
AID1578532Drug degradation assessed as methyl N-[(E)-8-[4-[(2E)-hexa-2,5-dienyl]-1,3-thiazol-2-yl]-3,7-dihydroxy-3-(hydroxymethyl)-8-methylnon-4-enyl]carbamate metabolite formation by measuring maximum absorbance units measured after preserving compound in amber vi2020ACS medicinal chemistry letters, Feb-13, Volume: 11, Issue:2
Reinvestigation of Mycothiazole Reveals the Penta-2,4-dien-1-ol Residue Imparts Picomolar Potency and 8
AID1578531Drug degradation assessed as methyl N-[(E)-8-[4-[(2E)-hexa-2,5-dienyl]-1,3-thiazol-2-yl]-3,7-dihydroxy-3-(hydroxymethyl)-8-methylnon-4-enyl]carbamate metabolite formation by measuring maximum absorbance units measured after preserving compound in amber vi2020ACS medicinal chemistry letters, Feb-13, Volume: 11, Issue:2
Reinvestigation of Mycothiazole Reveals the Penta-2,4-dien-1-ol Residue Imparts Picomolar Potency and 8
AID1578527Cytotoxicity against human HCT116 cells assessed as reduction in cell viability incubated for 3 days by tryphan blue dye based assay2020ACS medicinal chemistry letters, Feb-13, Volume: 11, Issue:2
Reinvestigation of Mycothiazole Reveals the Penta-2,4-dien-1-ol Residue Imparts Picomolar Potency and 8
AID1578526Cytotoxicity against human HepG2 cells assessed as reduction in cell viability incubated for 3 days by tryphan blue dye based assay2020ACS medicinal chemistry letters, Feb-13, Volume: 11, Issue:2
Reinvestigation of Mycothiazole Reveals the Penta-2,4-dien-1-ol Residue Imparts Picomolar Potency and 8
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (37.50)29.6817
2010's3 (37.50)24.3611
2020's2 (25.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.94 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]